NASDAQ:MNKD MannKind Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. $4.12 +0.07 (+1.73%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$4.01▼$4.3750-Day Range$2.67▼$4.7752-Week Range$2.49▼$5.44Volume5.51 million shsAverage Volume5.71 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MannKind MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside45.6% Upside$6.00 Price TargetShort InterestBearish16.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.60 out of 5 starsMedical Sector786th out of 1,433 stocksPharmaceutical Preparations Industry399th out of 683 stocks 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, MannKind has a forecasted upside of 45.6% from its current price of $4.12.Amount of Analyst CoverageMannKind has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.19% of the float of MannKind has been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in MannKind has recently increased by 6.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNKD. Previous Next 1.7 News and Social Media Coverage News SentimentMannKind has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.Search InterestOnly 13 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows12 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of MannKind is held by insiders.Percentage Held by Institutions43.57% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow in the coming year, from ($0.34) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -11.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -11.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address About MannKind (NASDAQ:MNKD) StockMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.Read More MNKD Stock News HeadlinesJune 26, 2022 | americanbankingnews.comMannKind (NASDAQ:MNKD) Stock Passes Above 200-Day Moving Average of $3.75June 20, 2022 | nasdaq.comAllogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last? - NasdaqJune 20, 2022 | finance.yahoo.comWhat Is The Ownership Structure Like For MannKind Corporation (NASDAQ:MNKD)?June 17, 2022 | americanbankingnews.comMannKind (NASDAQ:MNKD) Stock Price Down 5.6%June 3, 2022 | globenewswire.comMannkind to Host Product Theater and Booth at the American Diabetes Association's 82nd Scientific Sessions in New Orleans, June 3-7 - GlobeNewswireJune 3, 2022 | finance.yahoo.comMannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7June 2, 2022 | nasdaq.comJuly 22nd Options Now Available For MannKind (MNKD) - NasdaqJune 2, 2022 | streetinsider.comZealand Pharma (ZEAL) Appoints David M. Kendall as Chief Medical Officer - StreetInsider.comMay 28, 2022 | nasdaq.comJuly 8th Options Now Available For MannKind (MNKD)May 24, 2022 | benzinga.comMannKind Highlights FDA Approval Of United Therapeutics' Tyvaso DPI, Which Utilizes Technosphere Inhalati - BenzingaMay 24, 2022 | globenewswire.comMannKind's Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI - GlobeNewswireMay 24, 2022 | finance.yahoo.comMannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™May 24, 2022 | nasdaq.comMannKind Corporation Rings the Nasdaq Stock Market Opening BellMay 24, 2022 | nasdaq.comMannKind Corporation Rings the Opening BellMay 23, 2022 | benzinga.comUPDATE: FDA Doc For United Therapeutics, MannKind Lung Disease Therapy (Link In Body Of This Headline) - - BenzingaMay 23, 2022 | streetinsider.com"Approval of Tyvaso DPI Marks Significant Inflection Point", Shares Present "Upside From Current Levels" - Cantor Fitzgerald Bullish on MannKind (MNKD) with $6.50 Price Target - StreetInsider.comMay 23, 2022 | benzinga.com'United Therapeutics, MannKind gain as FDA approve lung disease therapy' - Seeking Alpha Blog Post From C - BenzingaMay 23, 2022 | marketwatch.comMannKind, United Therapeutics Rise on FDA Approval of Tyvaso DPI - MarketWatchMay 19, 2022 | globenewswire.comMannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma - GlobeNewswireMay 19, 2022 | globenewswire.comMannKind Corporation to Ring the Nasdaq Stock Market Opening Bell - GlobeNewswireMay 18, 2022 | marketwatch.comZealand Pharma Shares Rise 13% After MannKind Buys V-Go Insulin Delivery Device - MarketWatchMay 9, 2022 | benzinga.comMannKind Corporation Participating at Upcoming Conferences - Benzinga - BenzingaMay 6, 2022 | fool.comMannKind Corporation (MNKD) Q1 2022 Earnings Call Transcript - The Motley FoolMay 6, 2022 | finance.yahoo.comMannKind Corporation (MNKD) Q1 2022 Earnings Call TranscriptMay 6, 2022 | finance.yahoo.comMannKind Corporation Reports 2022 First Quarter Financial Results - Yahoo FinanceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees348Year Founded1991Company Calendar Last Earnings5/05/2022Today7/07/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+45.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,930,000.00 Net Margins-134.30% Pretax Margin-134.30% Return on EquityN/A Return on Assets-27.42% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.29 Sales & Book Value Annual Sales$75.44 million Price / Sales13.79 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / Book-4.96Miscellaneous Outstanding Shares252,570,000Free Float246,756,000Market Cap$1.04 billion OptionableOptionable Beta1.90 Social Links MannKind Frequently Asked Questions Should I buy or sell MannKind stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MannKind stock. View analyst ratings for MannKind or view top-rated stocks. What is MannKind's stock price forecast for 2022? 3 analysts have issued 12 month price targets for MannKind's shares. Their MNKD stock forecasts range from $6.00 to $6.00. On average, they expect MannKind's share price to reach $6.00 in the next year. This suggests a possible upside of 45.6% from the stock's current price. View analysts' price targets for MannKind or view top-rated stocks among Wall Street analysts. How has MannKind's stock performed in 2022? MannKind's stock was trading at $4.37 at the beginning of the year. Since then, MNKD stock has decreased by 5.7% and is now trading at $4.12. View the best growth stocks for 2022 here. When is MannKind's next earnings date? MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for MannKind. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.10). The biopharmaceutical company earned $11.99 million during the quarter, compared to the consensus estimate of $10.44 million. During the same period last year, the firm posted ($0.05) earnings per share. View MannKind's earnings history. Who are MannKind's key executives? MannKind's management team includes the following people: Dr. Michael E. Castagna Pharm.D., CEO & Director (Age 45, Pay $1.12M)Mr. Steven B. Binder, Chief Financial Officer (Age 59, Pay $772.05k) (LinkedIn Profile)Mr. Joseph Kocinsky M.B.A., M.S., Chief Technology Officer (Age 58, Pay $608.75k)Dr. David B. Thomson, Exec. VP, Gen. Counsel & Sec. (Age 55, Pay $772.9k) (LinkedIn Profile)Dr. Stuart A. Tross Ph.D., Chief People & Workplace Officer (Age 55, Pay $652.85k)Mr. Thomas Hofmann M.D., Ph.D., Chief Scientific OfficerMs. Rosabel Realica Alinaya, VP of Investor Relations & Treasury (Age 61)Mr. John F. Bedard, Sr. VP of Worldwide Regulatory Affairs (Age 72)Mr. James Patrick McCauley Jr., J.D., M.B.A., Chief Commercial Officer (Age 56)Mr. Alejandro Galindo M.B.A., M.S., Exec. VP of Endocrine Bus. Unit (Age 50) (LinkedIn Profile) Who are some of MannKind's key competitors? Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of MNKD's competitors. What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD). What is MannKind's stock symbol? MannKind trades on the NASDAQ under the ticker symbol "MNKD." How do I buy shares of MannKind? Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MannKind's stock price today? One share of MNKD stock can currently be purchased for approximately $4.12. How much money does MannKind make? MannKind (NASDAQ:MNKD) has a market capitalization of $1.04 billion and generates $75.44 million in revenue each year. The biopharmaceutical company earns $-80,930,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. How many employees does MannKind have? MannKind employs 348 workers across the globe. When was MannKind founded? MannKind was founded in 1991. How can I contact MannKind? MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for MannKind is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081. This page (NASDAQ:MNKD) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
